William Blair Predicts Lower Earnings for Sera Prognostics

Sera Prognostics, Inc. (NASDAQ:SERA) – William Blair dropped their Q3 2025 earnings per share (EPS) estimates for Sera Prognostics in a research report issued to clients and investors on Monday, February 3rd. William Blair analyst A. Brackmann now expects that the company will post earnings per share of ($0.24) for the quarter, down from their previous forecast of ($0.23). The consensus estimate for Sera Prognostics’ current full-year earnings is ($0.96) per share. William Blair also issued estimates for Sera Prognostics’ Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.98) EPS.

Sera Prognostics Stock Performance

NASDAQ SERA opened at $4.96 on Wednesday. The stock’s 50 day simple moving average is $7.31 and its 200-day simple moving average is $7.31. Sera Prognostics has a 1-year low of $4.61 and a 1-year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter last year, the business posted ($0.23) earnings per share.

Institutional Investors Weigh In On Sera Prognostics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in shares of Sera Prognostics by 10.6% in the fourth quarter. Rhumbline Advisers now owns 36,101 shares of the company’s stock valued at $294,000 after buying an additional 3,468 shares in the last quarter. Sanders Morris Harris LLC grew its stake in shares of Sera Prognostics by 165.7% in the fourth quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company’s stock valued at $725,000 after buying an additional 56,500 shares in the last quarter. Pallas Capital Advisors LLC acquired a new stake in shares of Sera Prognostics in the fourth quarter valued at $113,000. JPMorgan Chase & Co. grew its stake in shares of Sera Prognostics by 7,357.8% in the third quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock valued at $6,902,000 after buying an additional 873,002 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Sera Prognostics by 321.6% in the third quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after buying an additional 30,093 shares in the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.

Insider Activity

In related news, General Counsel Benjamin Jackson sold 13,272 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $7.42, for a total value of $98,478.24. Following the completion of the sale, the general counsel now owns 128,473 shares of the company’s stock, valued at approximately $953,269.66. This trade represents a 9.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Paul Kearney sold 4,078 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $29,850.96. Following the completion of the sale, the insider now directly owns 176,889 shares of the company’s stock, valued at approximately $1,294,827.48. This represents a 2.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 93,215 shares of company stock worth $666,835 over the last quarter. 15.80% of the stock is currently owned by corporate insiders.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.